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Research Article
Identification of potential complementary
serum biomarkers to differentiate prostate
cancer from benign prostatic hyperplasia
using gel- and lectin-based proteomics
analyses
Diagnosis of prostate cancer (PCa) is currently much reliant on the invasive and time-
consuming transrectal ultrasound-guided biopsy of the prostate gland, particularly in light
of the inefficient use of prostate-specific antigen as its biomarker. In the present study, we
have profiled the sera of patients with PCa and benign prostatic hyperplasia (BPH) using
the gel- and lectin-based proteomicsmethods and demonstrated the significant differential
expression of apolipoprotein AII, complement C3 beta chain fragment, inter-alpha-trypsin
inhibitor heavy chain 4 fragment, transthyretin, alpha-1-antitrypsin, and high molecular
weight kininogen (light chain) between the two groups of patients’ samples. Our data are
suggestive of the potential use of the serum proteins as complementary biomarkers to
effectively discriminate PCa from BPH, although this requires further extensive validation
on clinically representative populations.
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1 Introduction
Early benign prostatic hyperplasia (BPH) is an aging-
associated condition of enlarged prostate and voiding dys-
function often due to irregularities in cell proliferation and
detrusormuscle underactivity, respectively [1]. A similar clini-
cal presentation is also observed among patients with prostate
cancer (PCa) but involving cellular proliferation and differen-
tiation into themalignant stroma tissues and cells, instead [2].
An alarming escalating rate of incidences of PCa has
been observed both in Malaysia [3] and worldwide [4]. This is
partly due to increasinguse of serumprostate-specific antigen
(PSA) as a “screening tool” among men who were concerned
with PCa. Thus, the incidence of early-stage PCa is on the
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rise as the cancer is detected at an earlier stage rather than
the late metastatic stage. PCa is generally attributed to the
compounding effects of factors including aging [5], genetic
[6, 7], ethnicity [8], hereditary [9], and dietary intake [10]. It
is also well documented that the incidence of PCa increases
with age; rising to about 80% amongmen in their 80s [11,12].
The comprehensive approach to patients presenting with
lower urinary tract symptoms attributed to the prostate gland
involves digital rectal examination, uroflowmetry, postvoid
residual urine, urinalysis, assessment of validated Interna-
tional Prostate Symptom Score questionnaire, and the mea-
surement of serum PSA. In patients with a suspicious dig-
ital rectal examination of hard nodular prostate gland or a
raised PSA, a transrectal ultrasound (TRUS) guided biopsy
of the prostate gland is required so as to rule out any malig-
nancy on histopathology. Currently, PSA is the most widely
used biomarker for PCa but it lacks specificity and sensitivity.
Many benign pathologies such as BPH, inflammation, and
infection can often cause raised PSA [1, 13, 14], while on the
other hand, patients whose tissue sections demonstrated bel-
ligerent PCa features had been shown to have normal PSA
levels [15]. If specific biomarkers are made available, TRUS
biopsy can be done selectively, thus reducing significantly the
number of patients subjected to this procedure.
In light of the increasing incidences of PCa and the
failure of PSA to clearly distinguish BPH from PCa, novel
biomarkers that may be used to predict PCa at an early stage
with high specificity and efficiency are deemed necessary.
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These markers not only assist in the early and accurate iden-
tification of PCa patients thus paving the way for new cura-
tive treatment modalities but also alleviate needless anguish
of those with BPH. It was therefore the aim of the present
study to screen for potential serum biomarkers that can dis-
criminate PCa from BPH using proteomics analyses. Aside
from the conventional gel-based approach, we have also se-
lectively targeted at proteins that were O-glycosylated using a
lectin that binds to the O-glycans. Many O-glycoproteins had
previously been implicated with cancer [16–20]. It is therefore
interesting to determine if their levels were different between
patients with PCa and BPH.
2 Materials and methods
2.1 Patients’ serum samples
Collection of serum samples was done with patients’ con-
sent at the Prostate-TRUS Biopsy clinic, University of Malaya
Medical Center, Kuala Lumpur in accordance to a protocol
that was approved by the Medical Ethics Committee of the
center. Approximately 3 mL of blood was collected into plain
BD vacutainers (Becton, Dickinson & Co, Franklin Lakes,
New Jersey, USA) from subjects with BPH and newly di-
agnosed patients with stage I or II PCa. Designation of the
PCa stages were based on the American Joint Committee on
Cancer (AJCC) stage groupings that take both the TNM and
histopathological grading into consideration. The specimens
were left to stand at room temperature (RT) for 30min prior to
centrifugation. Serum samples were then carefully collected
and kept at –20C for further use.
2.2 Assay of PSA
Quantitative measurements of PSA in patients’ serum sam-
ples were performed according to themanufacturer’s instruc-
tionsusing theADVIACentaurSystem.Table 1 demonstrates
the demographics and mean PSA values of subjects involved
in the study.
Table 1. Demographic and clinical characteristics of subjects
Parameters BPH (n = 8) PCa (n = 8)
Ethnicity (M:C:Ia)) 1:5:2 2:5:1
Age (yearsb)) 65.3 ± 5.4 69.0 ± 3.6
PSAc) (ng/mLb)) 6.69 ± 1.73 29.60 ± 48.47
a) M:C:I refers to Malay:Chinese:Indian.
b) Values expressed in mean ± SD.
c) PSA values of 4 ng/mL or less are considered normal.
2.3 2DE
2DE was performed using 800 g protein for profiling of
neat serum samples (n = 8) or 60 g pooled O-glycoprotein
fractions of the same group of patients that were isolated
from champedak galactose binding (CGB) lectin affinity chro-
matography in a method that was previously described [21].
Samples were initially incubated in 2% v/v IPG sample buffer
pH 4–7, containing 9 M urea, 60 mMDTT, and 0.5% v/v Tri-
ton X-100 at room temperature for 30min. They were then in-
cubated in a rehydration solution containing 8 M urea, 0.5%
v/v IPG buffer, 0.5% v/v Triton X-100 for another 30 min.
IPG Immobiline Drystrips pH 4–7, 11 cm (GE Healthcare,
Uppsala, Sweden) were rehydrated in the solution contain-
ing the samples and rehydrated overnight. The strips were
subjected to isoelectric focusing using the Multiphor Flatbed
electrophoresis system (GE Healthcare) for a total duration
of 15 kV/h (Phase 1: 300 V, 2 mA, 5 W, 30 min; Phase 2:
3500 V, 2 mA, 5 W, ∼4–4.5 h). Focused strips were equi-
librated in 1.5 M Tris-HCl (pH 8.8) solution containing 6
M urea, 2% w/v SDS, 30% v/v glycerol, and 0.06 M DTT
for 15 min on a UNIMAX 2010 platform shaker (Heidolph,
Schwabach, Germany), and further incubated in a similar
equilibration solution but containing 4.5% v/v iodoacetamide
instead of DTT for another 15 min. The equilibrated strips
were overlaid onto 8–18% gradient polyacrylamide gels and
electrophoresis was performed following an optimized pro-
tocol (Phase 1: 50 V, 40 mA, 25 W for 30 min; Phase 2: 600V,
40mA, 25W for 1–2 h) using the SE 600Ruby Electrophoresis
System and Power Supply-EPS601 (GE Healthcare).
2.4 Silver staining of 2DE gels
Silver staining of the gels 2DE was performed according to
the method described by Heukeshoven and Dernick [22]. The
electrophoresed gels were initially fixed in a solution contain-
ing 40% v/v ethanol and 10% acetic acid for 30 min. This
was followed by incubation in 30% v/v ethanol solution con-
taining 0.5 M sodium acetate, 8 mM sodium thiosulfate, and
0.13% v/v glutaraldehyde for another 30 min. Gels were left
to stain in 5.9mM silver nitrite solution containing 0.02% v/v
formaldehyde for 40 min. The resolved proteins were visu-
alized by developing the gels with 0.24 M sodium carbonate
solution containing 0.2% v/v formaldehyde. The reaction was
finally stopped using a 40 mM EDTA-Na2.2H20 solution. For
each pooled serum sample, at least three 2DE gel separations
were performed. Gels were similarly subjected to the silver-
staining method for MS but in the absence of glutaraldehyde
[23].
2.5 Image analysis
Silver stained 2DE gels and lectin-probed NC blots were
scanned using Imaging Densitometer GS690 (Bio-Rad Labo-
ratories, Hercules, California, USA). Expression of proteins
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was analyzed in terms of the percentage of volume contribu-
tion using the Image Master 2D Platinum software, version
7.0 (GE Healthcare Biosciences, Uppsala, Sweden). Cut-off
parameters were: Smooth – 2; Saliency – 1; Min area – 5.
2.6 Western blotting and CGB lectin detection
The 2DE-separated proteins were transferred electrophoret-
ically onto NC membranes (0.45 mM; Whatman, Dassel,
Germany) using the NovaBlot Kit of the MultiphorTM II
Flatbed System (GE Healthcare Biosciences) for 2 h at a con-
stant current of 0.8 mA/cm2 gel. Detection of transferred
O-glycosylated serum proteins was performed using the CGB
lectin that was affinity purified and characterized for its speci-
ficity to O-glycans using methods that were previously re-
ported [24]. The lectin was then conjugated to horseradish
peroxidase before being used to probe forO-glycopeptides on
the NC membranes. The membranes were finally developed
by means of a colorimetric reaction using diamino-benzoic
acid (Bio-Rad Laboratories) as substrates.
2.7 CGB lectin affinity column chromatography
The affinity-purified CGB lectin was conjugated to CNBr-
activated Sepharose 4B according to the manufacturer’s in-
structions (Sigma Chemical, St. Louis, MO, USA). Column
was equilibrated with PBS pH 7.2, subsequent to application
of approximately 200 L serum samples that were pooled
from patients with PCa (n = 8) and BPH (n = 8). Fractions
were collected andmonitored for their absorbance at 280 nm.
Elution of bound O-glycoprotein-enriched fractions was per-
formed using 0.1 M melibiose in PBS. The bound fractions
were pooled and dialyzed against distilled water at 4C. The
dialysate was then lyophilized and kept at –20C for subse-
quent analysis by 2DE.
2.8 Trypsin digestion and MS
Identification of protein spots of interest was performed as
previously reported [25]. Spots were carefully excised from
2DE gels and destained with 15 mM potassium ferricyanide
in 50mMsodium thiosulphate for 15min at RT. The proteins
were reduced using 10 mM DTT in 100 mM ammonium bi-
carbonate solution for 30 min, and alkylated using 55 mM
iodoacetamide in the same solution for 20 min, at 60C and
in the dark. This was followed by sequential washings with
50 and 100% ACN, both in 100 mM ammonium bicarbon-
ate solution, and dehydration of the protein spots using vac-
uum centrifugation. The spots were digested with 6 ng/L
trypsin in 50mM ammonium bicarbonate at 37C, overnight.
Peptides were extracted from the gels using 50 and 100%
ACN. Extracted peptides were lyophilized, reconstituted in
0.1% formic acid, and desalted using the ZipTip columns
containing C18 reversed phase media (Millipore, MA, USA).
The sample peptide was mixed with 5 mg/mL -cyano-4-
hydroxycinnamic acid at a ratio of 1:1, and 0.7 L of the
mixture was immediately spotted onto an OptiTOF 384-well
insert and analyzed using the 4800 Plus MALDI TOF/TOF
analyzer (Applied Biosystem/MDS Sciex, Toronto, Canada).
2.9 Identification of proteins
Identification of proteins was performed using the
MASCOT search engine [26]. The MS data obtained was
searched against Homo sapien entries in the Swiss-Prot
database (Last update: 23 October 2008, containing 261 513
Figure 1. Typical silver stained 2DE protein profiles of sera from
patientswith BPH and PCa. (A) Patientswith BPH. (B) Patientswith
PCa. Proteins that were differentially expressed are marked on
the gels and their identities were confirmed by MS and database
search (please refer to Table 2).
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Table 2. Identification of serum proteins that were differentially expressed by MS/MS
Spot/ Matched Accession Theoretical Theoretical Mascot No. of Sequence
cluster protein number mass pI score peptides coverage
ID identity Swiss-Prot) (Da) matched (%)
APOA2 Apolipoprotein A-II P02652 11 168 6.26 51 1 11
C3f a) Complement C3 P01024 187 030 6.02 512 7 12
ITIH4f a) Inter-alpha-trypsin inhibitor heavy chain H4 Q14624 103 261 6.51 240 6 6
AAT Alpha-1 antitrypsin P01009 46 707 5.37 772 14 38
KNG High–molecular weight kininogen P01042 71 912 6.34 307 7 13
TTR Transthyretin P02766 15 877 5.52 511 6 49
a) Identified as a protein fragment as indicated by its position in the 2DE gels compared to the parent protein.
sequences) according to the following selection parameters:
enzyme – trypsin, missed cleavage – 1, variable modification
– 2; (i) carbamidomethylation of cysteine, and (ii) oxidation
of methionine, MS precursor ion mass tolerance – 100 ppm,
MS/MS fragment ion mass tolerance −0.2 Da, and inclusion
of monoisotopic masses only.
2.10 Statistical analysis
All values are expressed in mean ± SEM, unless otherwise
stated. The Statistical Package for Social Sciences (SPSS) ver-
sion 17.0 (IBM Corporation, Armonk, New York, USA) was
used to analyze the data of our study. The Student’s t-test
was subsequently used to compare means of percentage of
volume contribution of the spots between the study groups
for all datasets that showed normal distribution. A p value of
less than 0.01 was considered significant.
3 Results
Figure 1 demonstrates typical representative 2DE profiles
generated from neat sera of patients with BPH (panel A) and
PCa (panel B), respectively. The technique was able to resolve
more than 30 clusters of serum proteins that are relatively
of high abundance. However, comparative image analysis of
spot volumes of the serum proteins was generally not suc-
cessful in identifying those that may be specifically used to
differentiate BPH from PCa. Only two detected serum pro-
teins, whose identities were confirmed by subjecting their
excised 2DE gel spots to analysis by MS/MS and database
search (Table 2), were found to be differentially expressed.
Apolipoprotein AII (APOA2) and complement C3  chain
fragment (C3f), which are common proteins associated with
lipoprotein metabolism and general inflammation, respec-
tively, appeared to be downregulated in patients with PCa
compared to those with BPH (Fig. 2A and B). Aside from
the database search, C3f was identified on the basis of its
experimental Mr and MS/MS-derived sequences.
In an alternative approach, profiling of the serumwas se-
lectively targeted at proteins that were O-glycosylated. Many
O-glycoproteins had previously been implicated with cancer
[16–20], and it is therefore interesting to determine if their
levels were different between patients with PCa and those
with BPH. Figure 3 demonstrates the 2DE profiles of serum
O-glycoproteins of patients with PCa and BPH that was gen-
erated using enzyme-conjugated CGB lectin as probe. The
lectin was chosen on the basis of its specific binding to O-
glycans [24]. With exception of a 35-kDa fragment of ITIH4
(ITIH4f), the expression of all other O-glycopeptides was not
significantly altered between patients with BPH compared
to those with PCa. The expression of ITIH4f was apparently
lower in patients with PCa compared to those with BPH (Fig.
2C), but not significantly different when the western blot data
were compared to that similarly obtained froma control group
consisting of age-matched normal healthymale subjects (data
not shown).
In a separate attempt, we have also resorted to the use of
immobilized CGB lectin to selectively isolateO-glycoproteins
from pooled serum samples. Figure 4 demonstrates typi-
cal elution profiles from the affinity separation of pooled
serum samples of patients with BPH (panel A) and pooled
serum samples from patients with PCa (panel B). The ratio
of bound:total protein fractions was apparently similar for
both the pooled samples, which was approximately 0.09. A
total of 12 clusters of O-glycopeptides were apparently de-
tected when the enriched melibiose-eluted fractions from
BPH and PCa patients were separately dialyzed and subjected
to 2DE and silver staining (Fig. 5). Three peptide clusters were
found to be significantly enhanced in the sera of patients with
PCa compared to those with BPH when the 2DE gels were
scanned and analyzed by densitometry (Fig. 2D–F). These
clusters of peptides were later identified as transthyretin
(TTR), high-molecular weight kininogen (KNG), and alpha-
1-trypsin (AAT) (Table 2). We have also performed a study to
test for the possible nonspecific interaction between serum
proteins and chromatography media and found that there
was none.
4 Discussion
With exceptions of APOA2 and complement C3f, none of
the other high-abundance serum proteins were found to be
differentially expressed when 2DE protein profiles generated
from the sera of patients with BPHwere compared with those
generated from PCa patients’ sera. APOA2 is involved in the
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Figure 2. Volume contribution of proteins that were differen-
tially expressed between patients with BPH and PCa. Percent-
age of volume contribution of protein spots was analyzed us-
ing ImageMasterTM 2D Platinum software, version 7.0. (A and B)
Clusters of protein spots that were detected by silver staining
of 2DE gels (Fig. 1); (C) Analysis of O-glycopeptides detected by
enzyme-conjugated CGB lectin (Fig. 3). (D–F) Serum proteins that
were detected subsequent to CGB lectin affinity chromatography
(Fig. 5). The standard deviation (SD) shown in (A) and (B) are
from biological replicates while those in (C–F) are from technical
replicates.
metabolismof high-density lipoprotein and its deficiencymay
result in hypercholesterolemia [27]; while native C3 plays a
general role in the activation of both the classical and alter-
native pathways of complement and patients with deficiency
of C3 are generally susceptible to bacterial infection [28]. Due
to their nonspecific functions and association with diverse
pathological conditions, APOA2 and C3f may not be suit-
Figure 3. Detection of O-glycosylated serum proteins using
enzyme-conjugated CGB lectin. Enzyme-conjugated CGB lectin
was used to probe forO-glycosylated proteins fromsera thatwere
subjected to 2DE and transferred onto NCmembranes. Identity of
the sole protein that was differentially expressed was confirmed
by MS (please refer to Table 2). (A) Patients with BPH. (B) Patients
with PCa. The differentially expressed protein spots are marked
in boxes. Acidic sides of the NC membranes are to the left and
Mr declines from the top.
able for use as independent biomarkers. Nonetheless, it is
interesting to note that the 9-kDa C3 cleaved fragment, C3a,
has been reported to be elevated in patients with hepatocel-
lular carcinoma [29], breast cancer [30], and colorectal cancer
[31, 32]. This is compatible with the diminished amounts of
C3 seen in the PCa patients in this study.
When enzyme-conjugated CGB lectin was used to detect
2DE separated O-glycosylated proteins on NC membrane,
only ITIH4f was found to be differentially expressed. Con-
trary to our earlier expectation, expression of the 35-kDa O-
glycopeptide fragmentwas significantly lower in patientswith
PCa compared to those with BPH and its levels were not sig-
nificantly different compared to those obtained from normal
healthy control subjects. We have previously reported the
significant enhanced levels of ITIH4f selectively in patients
with cancers that are associated with increased levels of es-
trogens [24,26]. The sex steroid hormones may have induced
kallikrein to cleave native 120-kDa ITIH4 into its 85- and 35-
kDa fragments [33] in these cancers, the latter fragment of
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Figure 4. Isolation of O-glycosylated serum proteins using CGB
lectin affinity chromatography. Pooled serum samples from pa-
tients with BPH (A) and PCa (B) were separately subjected to CGB
lectin affinity chromatography. Collected fractions were moni-
tored by measurement of absorbance at 280 nm. Arrows indicate
start of elution using 0.1 M melibiose in PBS.
which is O-glycosylated and thus detected by the CGB lectin.
However, the data of the present study appear not to be in
line with our previous findings, as PCa is now known to be
associated with increased levels of serum estradiol [34]. The
different altered levels of ITIH4f expression in PCa and BPH
patients further suggest the contributing effect of androgens
since the hormones are also upregulated in patients with PCa
and that both estrogens and androgens are believed to be the
causing factors for prostate malignancy [35].
The use of immobilized CGB lectin in the affinity isola-
tion of O-glycosylated serum proteins from patients further
demonstrated the significant enhanced expression of KNG,
AAT, and TTR in serum samples of patients with PCa com-
pared to thosewith BPH. TheKNGspots that were resolved in
the 2DE gels were the O-glycosylated light chain component
of cleaved highmolecular weight kininogen. Our present data
appear to indicate that BPH and PCa are opposite of breast,
endometrial, and cervical cancers in their levels of serum
KNG since we had previously shown that KNG was depleted
in the women cancer patients [24]. This apparent contradic-
tion is again most likely attributed to the differences in the
ratio of the sex steroid hormones of men and women cancer
patients.
In cases of AAT and TTR, the mechanism by which they
were retained by the immobilized CGB lectin is not clear as
the proteins are not known to beO-glycosylated [36] and their
spot clusters were also not detected in the earlier western
Figure 5. Glycoproteomic profiling of O-glycosylated serum pro-
teins isolated by CGB lectin affinity chromatography. Pooled neat
serum samples were subjected to CGB lectin affinity chromatog-
raphy. Analysis of the CGB-bound fractions was performed by
2-DE and silver staining. (A) Patients with BPH. (B) Patients with
PCa. Identities of proteins that were differentially expressed were
confirmed by MS and database search (please refer to Table 2).
blot experiments that used enzyme-conjugated CGB lectin as
probe. Hence, their retention was most likely due to indirect
interactions with otherO-glycosylated serum proteins, which
are yet to be confirmed. While this is ambiguous for AAT,
it is not totally unexpected for TTR as the protein is rather
promiscuous in its interaction and is known to bind to many
aromatic compounds [37, 38]. TTR has been earlier identi-
fied as a potential biomarker for ovarian [39], colorectal [31],
and lung [40] cancers. It may have been retained by the CGB
lectin affinity column in this study via its interaction with
retinol–retinol binding protein 4 (RBP4) complex, although
it is currently not known if RBP4 is indeed O-glycosylated.
Alternatively, TTR could have interacted with the sex hor-
mone binding globulin (SHBG), which is known to possess
the O-linked oligosaccharides [41].
When taken together, the data of this study are suggestive
of the potential use of APOA2, C3f, ITIH4f, KNG, AAT, and
TTR as complementary biomarkers to effectively discrimi-
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nate PCa from BPH. It is hoped that the new biomarkers
would be able to assist clinicians in identifying patients who
are at a higher risk for PCa. However, this requires further
extensive validation in a study that has to be carefully de-
signed, particularly when the identified serum proteins have
been individually implicated in many other pathological con-
ditions. Such a study must also be carried out on clinically
representative populations and therefore not possibly per-
formed using the present gel- and lectin-based proteomics
approaches. With the identification of the potential biomark-
ers in the present study, validation is easily carried out in a
large-scale investigation using assays such as the simple or
multiplex ELISA.
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